Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Pontificia Universidad Javeriana Inicio
Ayuda y preguntas frecuentes
Español
English
Inicio
Perfiles
Unidades
Productos
Proyectos
Laboratorios y Equipos
Cursos
Actividades
Premios
Medios
Conjuntos de datos
Impacto
Tesis
Buscar por experiencia, nombre o afiliación
Type 2 inflammation in asthma and other airway diseases
Jorge Maspero
, Yochai Adir
, Mona Al-Ahmad
, Carlos A. Celis-Preciado
, Federico D. Colodenco
, Pedro Giavina-Bianchi
, Hani Lababidi
, Olivier Ledanois
, Bassam Mahoub
, Diahn Warng Perng
, Juan C. Vazquez
, Arzu Yorgancioglu
Departamento de Medicina Interna
Hospital Universitario San Ignacio
Universidad de Buenos Aires
Technion-Israel Institute of Technology
Kuwait University
Hospital Universitario San Ignacio
Hospital De Rehabilitación Respiratoria María Ferrer
Universidade de São Paulo
King Fahad Medical City
Sanofi-Aventis
Rashid Hospital
University of Sharjah
Veterans General Hospital-Taipei
Instituto Nacional de Enfermedades Respiratorias
Manisa Celal Bayar University
Producción
:
Contribución a una revista
›
Artículo de revisión
›
revisión exhaustiva
219
Citas (Scopus)
Información general
Huella
Huella
Profundice en los temas de investigación de 'Type 2 inflammation in asthma and other airway diseases'. En conjunto forman una huella única.
Clasificar por
Ponderación
Alfabéticamente
Keyphrases
Pathophysiology
100%
Asthma
100%
Interleukin-13 (IL-13)
100%
Type 2 Inflammation
100%
Airway Disease
100%
Interleukin-5 (IL-5)
66%
Interleukin-4 (IL-4)
66%
ILC2
66%
Chronic Inflammatory Airway Diseases
66%
Th2 Cells
66%
Disease Burden
33%
Pollutants
33%
Viral Infection
33%
B Cells
33%
Inflammation
33%
Targeted Therapy
33%
Global Health
33%
Inflammatory Mediators
33%
Innate Immune Response
33%
Best Medical Treatment
33%
Fungal Infection
33%
On-state Current
33%
Clinical Symptoms
33%
Mucus Production
33%
Eosinophils
33%
Adaptive Immune Response
33%
Standard of Care
33%
Health Anxiety
33%
Th2 Cytokines
33%
Chronic Rhinosinusitis
33%
Interleukin-4R
33%
Inhaled Corticosteroids
33%
Mepolizumab
33%
Treatment Practices
33%
Allergen
33%
Class Switching
33%
Eosinophilic COPD
33%
Barrier Disruption
33%
Disease Pathophysiology
33%
Cell Class
33%
Symptom Patterns
33%
Group 2 Innate Lymphoid Cells
33%
Benralizumab
33%
Reslizumab
33%
T Helper 2
33%
Poor Quality of Life
33%
Omalizumab
33%
Anti-IgE
33%
Allergic Rhinitis
33%
Dupilumab
33%
Improved Management
33%
Early Targeted Treatment
33%
Interleukin
33%
Asthma Control
33%
IgE Production
33%
Improved Patient Outcomes
33%
Goblet Cell Hyperplasia
33%
Tezepelumab
33%
Tissue Remodeling
33%
Inflammatory Airway Disease
33%
Barrier Tissue
33%
Global Initiative for Asthma Guidelines
33%
Medicine and Dentistry
Respiratory Disease
100%
Asthma
100%
Pathophysiology
80%
Interleukin 13
60%
Diseases
60%
Cytokine
40%
Targeted Therapy
40%
Th2 Cell
40%
Interleukin 5
40%
Interleukin 4
40%
Immunoglobulin E
40%
Hope
20%
Disease Burden
20%
Quality of Life
20%
B Cell
20%
Chronic Obstructive Pulmonary Disease
20%
Lymphoid Cell
20%
Biological Marker
20%
Virus Infection
20%
Inflammatory Mediator
20%
Mycosis
20%
Adaptive Immunity
20%
Allergic Rhinitis
20%
Dupilumab
20%
Goblet Cell
20%
Chronic Rhinosinusitis
20%
Benralizumab
20%
Tezepelumab
20%
Mucus
20%
Eosinophilic
20%
Innate Immunity
20%
Cell Hyperplasia
20%
Allergen
20%
Interleukin Derivative
20%
Omalizumab
20%
Reslizumab
20%
Mepolizumab
20%
Eosinophil
20%
Clinical Symptom
20%
Pharmacology, Toxicology and Pharmaceutical Science
Respiratory Tract Disease
100%
Asthma
100%
Inflammation
100%
Pathophysiology
80%
Diseases
80%
Interleukin 13
60%
Cytokine
40%
Interleukin 4
40%
Interleukin 5
40%
Immunoglobulin E
40%
Chronic Obstructive Lung Disease
20%
Virus Infection
20%
Chronic Rhinosinusitis
20%
Biological Marker
20%
Mycosis
20%
Allergen
20%
Dupilumab
20%
Allergic Rhinitis
20%
Mepolizumab
20%
Omalizumab
20%
Cell Hyperplasia
20%
Reslizumab
20%
Interleukin Derivative
20%
Benralizumab
20%
Tezepelumab
20%
Immunology and Microbiology
Asthma
100%
Airway
100%
Interleukin 13
60%
Immunoglobulin E
40%
Cytokine
40%
Interleukin 5
40%
Interleukin 4
40%
Th2 Cell
40%
B Cell
20%
Innate Immune System
20%
Adaptive Immune System
20%
Innate Lymphoid Cell
20%
Agonist
20%
Mediator
20%
Disease Burden
20%
Allergen
20%
Interleukin Derivative
20%
Omalizumab
20%
Goblet Cell
20%
Tezepelumab
20%
Mepolizumab
20%
Allergic Rhinitis
20%
Benralizumab
20%
Reslizumab
20%
Dupilumab
20%
Eosinophil
20%
Infection
20%
INIS
diseases
100%
interleukins
100%
inflammation
100%
asthma
100%
production
22%
tissues
22%
patients
22%
symptoms
22%
therapy
22%
management
11%
control
11%
guidelines
11%
pollutants
11%
barriers
11%
quality of life
11%
biological markers
11%
cytokines
11%
lymphoid cells
11%
corticosteroids
11%
eosinophils
11%